Terminated PHASE2 INTERVENTIONAL NCT00089713

Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients

Sponsor: Synvista Therapeutics, Inc

Conditions Hypertension

Interventions alagebrium chloride (ALT-711)

Updated 5 times since 2017 Last updated: Feb 5, 2010 Started: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

A PHASE2 clinical study on Hypertension, this trial is terminated or withdrawn. The trial is conducted by Synvista Therapeutics, Inc and has accumulated 5 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Synvista Therapeutics, Inc

Data source: Synvista Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Parsippany, United States